PMID- 38115203
OWN - NLM
STAT- MEDLINE
DCOM- 20240304
LR  - 20240304
IS  - 1447-0756 (Electronic)
IS  - 1341-8076 (Linking)
VI  - 50
IP  - 3
DP  - 2024 Mar
TI  - Increase in creatinine levels associated with niraparib maintenance therapy in 
      ovarian cancer.
PG  - 501-507
LID - 10.1111/jog.15865 [doi]
AB  - AIM: In Japan, Niraparib maintenance therapy for primary and recurrent ovarian 
      cancer was approved in September 2020 and is expected to improve the prognosis of 
      ovarian cancer. However, the safety of niraparib maintenance therapy in Japanese 
      patients has not been fully evaluated. METHODS: Patients with ovarian cancer 
      (including fallopian tube and peritoneal cancer) treated with niraparib at Jichi 
      Medical University Hospital from September 2020 to August 2022 were enrolled in 
      this study. Patient background, starting dose, rates of interruption, reduction, 
      or discontinuation, adverse events (AEs) during treatment, and estimated 
      glomerular filtration rate (eGFR) trends were retrospectively analyzed. RESULTS: 
      Twenty-nine patients received niraparib maintenance therapy during the study 
      period, including 21 with primary cancer and 8 patients with recurrent cancer. 
      Seventeen patients (58.6%) required dose interruptions and 16 patients (55.2%) 
      required dose reductions. Only two patients (6.9%) discontinued treatment due to 
      fatigue and nausea. The most frequent AE was creatinine increases in 18 patients 
      (62.1%, all grades). Although eGFR levels decreased significantly after niraparib 
      therapy compared to before niraparib therapy (59.3 vs. 50.3 mL/min/1.73 m(2) , 
      p < 0.001), the levels returned to pre-niraparib initiation levels after 
      discontinuation of niraparib (64.6 vs. 64.6 mL/min/1.73 m(2) , p = 0.96). 
      Multivariate regression analysis showed that diabetes was independently 
      associated with decreased eGFR (p = 0.013). CONCLUSIONS: Niraparib maintenance 
      therapy frequently increased serum creatinine, but the change was reversible. 
      Further studies are needed to determine the effects of niraparib on renal 
      function in Japanese patients.
CI  - (c) 2023 Japan Society of Obstetrics and Gynecology.
FAU - Takahashi, Yoshifumi
AU  - Takahashi Y
AUID- ORCID: 0000-0003-3319-1205
AD  - Department of Obstetrics and Gynecology, School of Medicine, Jichi Medical 
      University, Shimotsuke, Tochigi, Japan.
FAU - Taguchi, Masahiro
AU  - Taguchi M
AD  - Department of Obstetrics and Gynecology, School of Medicine, Jichi Medical 
      University, Shimotsuke, Tochigi, Japan.
FAU - Tamura, Kohei
AU  - Tamura K
AUID- ORCID: 0000-0003-3278-7509
AD  - Department of Obstetrics and Gynecology, School of Medicine, Jichi Medical 
      University, Shimotsuke, Tochigi, Japan.
FAU - Shinohara, Miki
AU  - Shinohara M
AD  - Department of Obstetrics and Gynecology, School of Medicine, Jichi Medical 
      University, Shimotsuke, Tochigi, Japan.
FAU - Koyanagi, Takahiro
AU  - Koyanagi T
AD  - Department of Obstetrics and Gynecology, School of Medicine, Jichi Medical 
      University, Shimotsuke, Tochigi, Japan.
FAU - Takahashi, Suzuyo
AU  - Takahashi S
AD  - Department of Obstetrics and Gynecology, School of Medicine, Jichi Medical 
      University, Shimotsuke, Tochigi, Japan.
FAU - Taneichi, Akiyo
AU  - Taneichi A
AD  - Department of Obstetrics and Gynecology, School of Medicine, Jichi Medical 
      University, Shimotsuke, Tochigi, Japan.
FAU - Takei, Yuji
AU  - Takei Y
AUID- ORCID: 0000-0002-1744-5570
AD  - Department of Obstetrics and Gynecology, School of Medicine, Jichi Medical 
      University, Shimotsuke, Tochigi, Japan.
FAU - Saga, Yasushi
AU  - Saga Y
AD  - Department of Obstetrics and Gynecology, School of Medicine, Jichi Medical 
      University, Shimotsuke, Tochigi, Japan.
FAU - Fujiwara, Hiroyuki
AU  - Fujiwara H
AD  - Department of Obstetrics and Gynecology, School of Medicine, Jichi Medical 
      University, Shimotsuke, Tochigi, Japan.
LA  - eng
PT  - Journal Article
DEP - 20231219
PL  - Australia
TA  - J Obstet Gynaecol Res
JT  - The journal of obstetrics and gynaecology research
JID - 9612761
RN  - HMC2H89N35 (niraparib)
RN  - AYI8EX34EU (Creatinine)
RN  - 0 (Indazoles)
RN  - 0 (Piperidines)
SB  - IM
MH  - Female
MH  - Humans
MH  - Creatinine
MH  - Retrospective Studies
MH  - *Neoplasm Recurrence, Local
MH  - *Ovarian Neoplasms/drug therapy
MH  - *Indazoles
MH  - *Piperidines
OTO - NOTNLM
OT  - creatinine increase
OT  - diabetes
OT  - eGFR
OT  - niraparib
OT  - ovarian cancer
EDAT- 2023/12/20 06:42
MHDA- 2024/03/04 06:44
CRDT- 2023/12/20 00:30
PHST- 2023/06/26 00:00 [received]
PHST- 2023/12/07 00:00 [accepted]
PHST- 2024/03/04 06:44 [medline]
PHST- 2023/12/20 06:42 [pubmed]
PHST- 2023/12/20 00:30 [entrez]
AID - 10.1111/jog.15865 [doi]
PST - ppublish
SO  - J Obstet Gynaecol Res. 2024 Mar;50(3):501-507. doi: 10.1111/jog.15865. Epub 2023 
      Dec 19.